Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rectal Neoplasms | 11 | 2024 | 1152 | 1.650 |
Why?
|
Security Measures | 1 | 2018 | 82 | 0.610 |
Why?
|
Labor, Induced | 1 | 2018 | 151 | 0.570 |
Why?
|
Oropharyngeal Neoplasms | 2 | 2017 | 491 | 0.490 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 494 | 0.460 |
Why?
|
Ontario | 8 | 2017 | 397 | 0.460 |
Why?
|
Physician Assistants | 1 | 2016 | 188 | 0.440 |
Why?
|
Digestive System Surgical Procedures | 2 | 2015 | 575 | 0.430 |
Why?
|
Infant, Premature, Diseases | 1 | 2018 | 708 | 0.420 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2015 | 357 | 0.390 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2018 | 833 | 0.390 |
Why?
|
Rectum | 2 | 2019 | 895 | 0.380 |
Why?
|
Workload | 1 | 2016 | 847 | 0.340 |
Why?
|
Patient Care Planning | 1 | 2015 | 907 | 0.340 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2018 | 2416 | 0.340 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 931 | 0.330 |
Why?
|
Disease Outbreaks | 1 | 2018 | 1755 | 0.320 |
Why?
|
Lung Neoplasms | 6 | 2018 | 13245 | 0.320 |
Why?
|
Guideline Adherence | 1 | 2018 | 2215 | 0.310 |
Why?
|
Patient Care Team | 2 | 2016 | 2504 | 0.290 |
Why?
|
Medical Oncology | 6 | 2019 | 2312 | 0.280 |
Why?
|
Esophageal Neoplasms | 3 | 2023 | 1648 | 0.280 |
Why?
|
Attitude of Health Personnel | 4 | 2016 | 3867 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2017 | 5246 | 0.280 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2796 | 0.270 |
Why?
|
Practice Guidelines as Topic | 9 | 2024 | 7377 | 0.270 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2024 | 2292 | 0.270 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2751 | 0.250 |
Why?
|
Sentinel Lymph Node Biopsy | 4 | 2017 | 733 | 0.250 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2017 | 4023 | 0.250 |
Why?
|
Liver Neoplasms | 4 | 2024 | 4313 | 0.250 |
Why?
|
Colonic Neoplasms | 3 | 2022 | 2523 | 0.250 |
Why?
|
Antineoplastic Agents | 6 | 2019 | 13591 | 0.250 |
Why?
|
Protein Kinase Inhibitors | 2 | 2018 | 5629 | 0.240 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2019 | 3990 | 0.230 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2021 | 3527 | 0.220 |
Why?
|
Neoplasm Staging | 11 | 2021 | 11152 | 0.220 |
Why?
|
Patient Preference | 1 | 2011 | 921 | 0.220 |
Why?
|
Fertility | 2 | 2019 | 773 | 0.220 |
Why?
|
Stomach Neoplasms | 2 | 2023 | 1422 | 0.210 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2019 | 1791 | 0.210 |
Why?
|
Elastin | 2 | 2022 | 300 | 0.210 |
Why?
|
Colorectal Neoplasms | 6 | 2022 | 6852 | 0.200 |
Why?
|
Decision Support Techniques | 2 | 2020 | 1996 | 0.190 |
Why?
|
Anti-Infective Agents | 2 | 2019 | 981 | 0.190 |
Why?
|
Neoadjuvant Therapy | 4 | 2024 | 2821 | 0.190 |
Why?
|
Intestinal Neoplasms | 1 | 2023 | 311 | 0.180 |
Why?
|
Quality of Health Care | 1 | 2016 | 4317 | 0.180 |
Why?
|
Decision Support Systems, Clinical | 1 | 2010 | 1162 | 0.180 |
Why?
|
Radiology | 1 | 2014 | 2102 | 0.180 |
Why?
|
Neoplasms | 9 | 2019 | 22030 | 0.170 |
Why?
|
Patient Selection | 2 | 2020 | 4244 | 0.170 |
Why?
|
Oocyte Donation | 1 | 2019 | 52 | 0.160 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 8530 | 0.150 |
Why?
|
Humans | 60 | 2024 | 758381 | 0.150 |
Why?
|
Radiosurgery | 2 | 2017 | 1342 | 0.150 |
Why?
|
Microsatellite Instability | 1 | 2021 | 715 | 0.150 |
Why?
|
Birth Rate | 1 | 2019 | 168 | 0.150 |
Why?
|
Term Birth | 1 | 2018 | 140 | 0.150 |
Why?
|
Hazardous Substances | 1 | 2019 | 152 | 0.150 |
Why?
|
Colectomy | 2 | 2022 | 692 | 0.150 |
Why?
|
Veins | 1 | 2022 | 765 | 0.150 |
Why?
|
Biliary Tract Neoplasms | 1 | 2019 | 184 | 0.140 |
Why?
|
Neuroendocrine Tumors | 1 | 2023 | 650 | 0.140 |
Why?
|
Ambulatory Care | 2 | 2018 | 2768 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 5 | 2021 | 36285 | 0.140 |
Why?
|
Government Programs | 1 | 2018 | 279 | 0.130 |
Why?
|
Pregnancy Rate | 1 | 2019 | 649 | 0.130 |
Why?
|
Quality Improvement | 3 | 2017 | 3806 | 0.130 |
Why?
|
Internship and Residency | 1 | 2016 | 5865 | 0.130 |
Why?
|
Neoplasm Invasiveness | 3 | 2022 | 3617 | 0.120 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2019 | 557 | 0.120 |
Why?
|
Oncology Service, Hospital | 1 | 2015 | 58 | 0.120 |
Why?
|
Postoperative Complications | 3 | 2020 | 15638 | 0.120 |
Why?
|
Melanoma | 3 | 2017 | 5691 | 0.120 |
Why?
|
Lymph Nodes | 2 | 2017 | 3485 | 0.120 |
Why?
|
Radiation Oncology | 2 | 2017 | 563 | 0.120 |
Why?
|
Lymph Node Excision | 2 | 2017 | 1303 | 0.120 |
Why?
|
Vascular Neoplasms | 1 | 2016 | 167 | 0.120 |
Why?
|
Referral and Consultation | 2 | 2019 | 3586 | 0.110 |
Why?
|
Physician's Role | 2 | 2019 | 917 | 0.110 |
Why?
|
Pancreatic Neoplasms | 2 | 2023 | 5349 | 0.110 |
Why?
|
Immunocompromised Host | 1 | 2018 | 856 | 0.110 |
Why?
|
General Surgery | 2 | 2016 | 1677 | 0.110 |
Why?
|
Medical Audit | 1 | 2014 | 452 | 0.100 |
Why?
|
Neutropenia | 1 | 2018 | 884 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11709 | 0.100 |
Why?
|
Prescription Drugs | 1 | 2019 | 627 | 0.100 |
Why?
|
Vulvar Neoplasms | 1 | 2015 | 263 | 0.100 |
Why?
|
Occupational Health | 1 | 2019 | 805 | 0.100 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2016 | 496 | 0.100 |
Why?
|
International Cooperation | 1 | 2018 | 1430 | 0.100 |
Why?
|
Preoperative Period | 1 | 2014 | 553 | 0.100 |
Why?
|
Erectile Dysfunction | 1 | 2015 | 451 | 0.100 |
Why?
|
Work Schedule Tolerance | 1 | 2016 | 551 | 0.100 |
Why?
|
Delivery, Obstetric | 1 | 2018 | 932 | 0.090 |
Why?
|
Medical Staff, Hospital | 1 | 2015 | 600 | 0.090 |
Why?
|
Evidence-Based Medicine | 6 | 2019 | 3671 | 0.090 |
Why?
|
Fertilization in Vitro | 1 | 2019 | 1292 | 0.090 |
Why?
|
Infection Control | 1 | 2018 | 982 | 0.090 |
Why?
|
Program Development | 1 | 2017 | 1297 | 0.090 |
Why?
|
Fever | 1 | 2018 | 1617 | 0.090 |
Why?
|
Clinical Competence | 5 | 2019 | 4775 | 0.090 |
Why?
|
Cesarean Section | 1 | 2018 | 1385 | 0.090 |
Why?
|
Genital Neoplasms, Female | 1 | 2015 | 533 | 0.090 |
Why?
|
Gestational Age | 1 | 2018 | 3565 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1415 | 0.080 |
Why?
|
Female | 22 | 2022 | 390316 | 0.080 |
Why?
|
Hepatic Insufficiency | 1 | 2009 | 14 | 0.080 |
Why?
|
Documentation | 1 | 2015 | 892 | 0.080 |
Why?
|
Immunotherapy | 2 | 2023 | 4641 | 0.080 |
Why?
|
Longitudinal Studies | 2 | 2015 | 14481 | 0.080 |
Why?
|
Infant, Premature | 1 | 2018 | 2092 | 0.080 |
Why?
|
Interviews as Topic | 2 | 2019 | 2675 | 0.080 |
Why?
|
Sleep Deprivation | 1 | 2015 | 840 | 0.080 |
Why?
|
Pregnancy Outcome | 1 | 2019 | 2907 | 0.080 |
Why?
|
Benzenesulfonates | 1 | 2009 | 165 | 0.080 |
Why?
|
Occupational Exposure | 1 | 2019 | 1809 | 0.080 |
Why?
|
Societies, Medical | 2 | 2017 | 3891 | 0.080 |
Why?
|
Fatigue | 1 | 2015 | 1542 | 0.080 |
Why?
|
Skin Neoplasms | 2 | 2017 | 5797 | 0.080 |
Why?
|
Canada | 3 | 2019 | 2111 | 0.080 |
Why?
|
Treatment Outcome | 8 | 2022 | 64379 | 0.070 |
Why?
|
Needs Assessment | 1 | 2013 | 1141 | 0.070 |
Why?
|
Vaccines | 1 | 2015 | 832 | 0.070 |
Why?
|
Depression | 2 | 2016 | 8057 | 0.070 |
Why?
|
Mammography | 1 | 2017 | 2427 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2024 | 10146 | 0.070 |
Why?
|
Male | 16 | 2022 | 358742 | 0.070 |
Why?
|
Colonoscopy | 1 | 2014 | 1388 | 0.070 |
Why?
|
Diffusion of Innovation | 1 | 2010 | 728 | 0.060 |
Why?
|
Staining and Labeling | 2 | 2022 | 1083 | 0.060 |
Why?
|
Adult | 12 | 2022 | 219916 | 0.060 |
Why?
|
Adenocarcinoma | 1 | 2021 | 6313 | 0.060 |
Why?
|
Quality Assurance, Health Care | 1 | 2014 | 2167 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3425 | 0.060 |
Why?
|
Middle Aged | 11 | 2022 | 219560 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 2882 | 0.050 |
Why?
|
Renal Insufficiency | 1 | 2009 | 809 | 0.050 |
Why?
|
Disease Management | 3 | 2018 | 2500 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2010 | 2432 | 0.050 |
Why?
|
Methyl Green | 1 | 2022 | 6 | 0.050 |
Why?
|
Retrospective Studies | 7 | 2021 | 80170 | 0.050 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2022 | 69 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2020 | 9273 | 0.050 |
Why?
|
Azo Compounds | 1 | 2022 | 117 | 0.050 |
Why?
|
Somatostatin | 1 | 2023 | 447 | 0.050 |
Why?
|
Mass Screening | 1 | 2017 | 5425 | 0.050 |
Why?
|
Sex Factors | 1 | 2015 | 10505 | 0.050 |
Why?
|
Early Detection of Cancer | 2 | 2014 | 3211 | 0.050 |
Why?
|
Prospective Studies | 2 | 2015 | 54136 | 0.050 |
Why?
|
Esophagogastric Junction | 1 | 2023 | 341 | 0.040 |
Why?
|
Aged | 8 | 2022 | 168217 | 0.040 |
Why?
|
Endothelial Growth Factors | 1 | 2022 | 672 | 0.040 |
Why?
|
Pregnancy | 2 | 2019 | 29742 | 0.040 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2012 | 2016 | 0.040 |
Why?
|
Leucovorin | 1 | 2021 | 641 | 0.040 |
Why?
|
Coloring Agents | 1 | 2022 | 560 | 0.040 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2021 | 243 | 0.040 |
Why?
|
Logistic Models | 2 | 2012 | 13276 | 0.040 |
Why?
|
Depressive Disorder, Major | 1 | 2016 | 4745 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3099 | 0.040 |
Why?
|
Anxiety | 1 | 2013 | 4538 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2017 | 2943 | 0.040 |
Why?
|
Disease Progression | 1 | 2015 | 13468 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2018 | 26182 | 0.040 |
Why?
|
Prevalence | 1 | 2015 | 15646 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2022 | 15225 | 0.040 |
Why?
|
Psychotherapy | 2 | 2016 | 1640 | 0.040 |
Why?
|
Pyridines | 1 | 2009 | 2860 | 0.040 |
Why?
|
Fluorouracil | 1 | 2021 | 1631 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2022 | 58681 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2019 | 627 | 0.030 |
Why?
|
Breast Neoplasms | 3 | 2019 | 21017 | 0.030 |
Why?
|
Quality of Life | 1 | 2017 | 13286 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 638 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 851 | 0.030 |
Why?
|
Mycoses | 1 | 2018 | 386 | 0.030 |
Why?
|
Remission Induction | 1 | 2020 | 2388 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2019 | 870 | 0.030 |
Why?
|
Risk Assessment | 3 | 2022 | 23883 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 567 | 0.030 |
Why?
|
Communication | 2 | 2019 | 3846 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2020 | 1268 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1722 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14641 | 0.030 |
Why?
|
Equipment and Supplies | 1 | 2015 | 273 | 0.030 |
Why?
|
Antifungal Agents | 1 | 2018 | 749 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2018 | 642 | 0.030 |
Why?
|
Cohort Studies | 1 | 2015 | 41252 | 0.030 |
Why?
|
United States | 2 | 2017 | 72140 | 0.030 |
Why?
|
Life Change Events | 1 | 2017 | 953 | 0.020 |
Why?
|
Urban Health Services | 1 | 2012 | 176 | 0.020 |
Why?
|
Oocytes | 1 | 2016 | 1165 | 0.020 |
Why?
|
Cryopreservation | 1 | 2016 | 717 | 0.020 |
Why?
|
Prognosis | 3 | 2019 | 29558 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4839 | 0.020 |
Why?
|
Cisplatin | 1 | 2017 | 1645 | 0.020 |
Why?
|
Specialties, Surgical | 1 | 2015 | 388 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2016 | 1674 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1725 | 0.020 |
Why?
|
Biopsy | 1 | 2022 | 6768 | 0.020 |
Why?
|
Outpatients | 1 | 2018 | 1591 | 0.020 |
Why?
|
Anti-Bacterial Agents | 2 | 2019 | 7403 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2018 | 1401 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1501 | 0.020 |
Why?
|
Hepatectomy | 1 | 2012 | 559 | 0.020 |
Why?
|
Morbidity | 1 | 2014 | 1754 | 0.020 |
Why?
|
Risk Factors | 3 | 2022 | 73806 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6821 | 0.020 |
Why?
|
Time Factors | 2 | 2021 | 39873 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1386 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4901 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2553 | 0.020 |
Why?
|
Focus Groups | 1 | 2012 | 1382 | 0.020 |
Why?
|
Young Adult | 3 | 2022 | 58808 | 0.020 |
Why?
|
Niacinamide | 1 | 2009 | 414 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2009 | 529 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2018 | 4485 | 0.020 |
Why?
|
Genetic Testing | 1 | 2018 | 3530 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11070 | 0.010 |
Why?
|
Antidepressive Agents | 1 | 2016 | 2889 | 0.010 |
Why?
|
Mortality | 1 | 2015 | 2885 | 0.010 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1797 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2016 | 3242 | 0.010 |
Why?
|
Contrast Media | 1 | 2016 | 5298 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18357 | 0.010 |
Why?
|
Patient Readmission | 1 | 2015 | 3261 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 3993 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2021 | 8981 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12096 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2013 | 25953 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2013 | 39060 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 87888 | 0.010 |
Why?
|